620 / 1726
Stage I intermediate risk (n=714):
•
grade 1 or 2 with
≥50% invasion
•
grade 2 or 3 with <50% invasion
•
TAH-BSO without lymphadenectomy
R
pelvic radiotherapy
no further treatment
Creutzberg et al, Lancet 2000
PORTEC-1 trial (1990-1997)
46 Gy / 23# / 5 wks